CrossRef The Enterolimbic Axis: Gut-Brain Affective Circuits at the Crossroad of Metabolism, Emotion, and Behavior Antonio Gasbarrini, Francesca Sofia Galli, Gianluca Ianiro, Francesca Ponziani, Emanuele Rinninella American Journal of Gastroenterology.2026;[Epub] CrossRef Micronutrient Deficiencies in the Era of Second-Generation Incretin-Based Therapies for Obesity Andrijana Koceva, Andrej Jane, Tajda Peko, Mojca Jensterle Nutrients.2026
Ozempic (semaglutide) is a GLP-1 receptor agonist approved for type 2 diabetes
GLP-1 medications should not be used together with DPP-4 inhibitors (medicines that increase natural GLP-1 levels) because this combination adds no extra benefit and may increase side effects
The largest percentage-based losses often occur in the first 6 months, with the weight loss trajectory gradually leveling after 12-18 months as the body approaches a new equilibrium
Ebenso wenig lassen die auf Koerpergewicht bezogenen Tierdosen einen Rueckschluss auf ein sinnvolles Humanprotokoll zu, da sich Rezeptordichte, Clearance und Verteilungsvolumen zwischen den Spezies unterscheiden